# Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

> **NCT02331251** · PHASE1,PHASE2 · TERMINATED · sponsor: **Western Regional Medical Center** · enrollment: 81 (actual)

## Conditions studied

- Advanced Cancer
- Breast Cancer
- Sarcoma
- Pancreatic Cancer
- Small Cell Lung Cancer
- Ovarian

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Vinorelbine
- **DRUG:** Irinotecan
- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT02331251
- **Lead sponsor:** Western Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** PI not longer at site.
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02331251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02331251, "Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02331251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*